Literature DB >> 15667918

Acute quadriplegia complicating critical illness polyneuropathy in a patient with infective endocarditis: a case report.

Hsiang-Cheng Chen1, Chien-Sung Tsai, Jiunn-Tay Lee, Chuu-An Chen, Feng-Yee Chang.   

Abstract

A 75-year-old woman with infective endocarditis developed critical illness polyneuropathy (CIP) with quadriplegia after cardiac surgery. The quadriplegia resolved gradually after aggressive treatment of the underlying infection and with rehabilitation. However, a MEDLINE search of the English-language literature failed to yield results matching quadriplegia and infective endocarditis. CIP is a complication of septic syndrome and sepsis. This complication has been largely unrecognized in intensive care units owing to difficulties in performing a clinical examination or electrophysiologic studies. Difficulty in weaning from the ventilator is an important early manifestation of CIP. Electroneuromyography (ENMG) should be routinely performed to establish the diagnosis. We suggest that any septic patients with unexplained muscle weakness, paralysis, or difficulty in weaning from the ventilator should be evaluated for CIP.

Entities:  

Mesh:

Year:  2005        PMID: 15667918     DOI: 10.1016/j.jinf.2003.11.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

1.  Acute inflammatory demyelinating polyneuropathy and a unilateral babinski/plantar reflex.

Authors:  Davide Cattano; Brian O'connor; Ra'ad Shakir; Francesco Giunta; Mark Palazzo
Journal:  Anesthesiol Res Pract       Date:  2007-11-12

2.  Facial nerve involvement in critical illness polyneuropathy.

Authors:  Mohan Gurjar; Afzal Azim; Arvind K Baronia; Banani Poddar
Journal:  Indian J Anaesth       Date:  2010-09

3.  beta-Neurexin is a ligand for the Staphylococcus aureus MSCRAMM SdrC.

Authors:  E Magda Barbu; Vannakambadi K Ganesh; Shivasankarappa Gurusiddappa; R Chris Mackenzie; Timothy J Foster; Thomas C Sudhof; Magnus Höök
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.